Quality evaluation of the research literature on the pharmacoeconomics of traditional Chinese medicines in China from 2018 to 2022

LI Wenshuang; DAI Zeqi; SUN Qingran; WAN Chuchuan; LIAO Xing; XI Xiaoyu

doi:10.6039/j.issn.1001-0408.2023.19.13

您当前的位置：

首页 >

文章列表页 >

Quality evaluation of the research literature on the pharmacoeconomics of traditional Chinese medicines in China from 2018 to 2022

更新时间：2023-10-09

- Quality evaluation of the research literature on the pharmacoeconomics of traditional Chinese medicines in China from 2018 to 2022
- ZHONGGUO YAOFANG Vol. 34, Issue 19, Pages: 2378-2384(2023)
- 作者机构：
  
  1.中国药科大学国家药物政策与医药产业经济研究中心，南京　211198
  2.中国中医科学院中医临床基础医学研究所，北京　100700
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.19.13
  CLC： R956;R28
- Published：15 October 2023，
  
  Received：30 March 2023，
  
  Revised：07 September 2023，
扫描看全文
李文爽,戴泽琦,孙庆冉等.2018－2022年我国中药药物经济学研究文献的质量评价 ^Δ[J].中国药房,2023,34(19):2378-2384.

LI Wenshuang,DAI Zeqi,SUN Qingran,et al.Quality evaluation of the research literature on the pharmacoeconomics of traditional Chinese medicines in China from 2018 to 2022[J].ZHONGGUO YAOFANG,2023,34(19):2378-2384.
李文爽,戴泽琦,孙庆冉等.2018－2022年我国中药药物经济学研究文献的质量评价 ^Δ[J].中国药房,2023,34(19):2378-2384. DOI： 10.6039/j.issn.1001-0408.2023.19.13.

LI Wenshuang,DAI Zeqi,SUN Qingran,et al.Quality evaluation of the research literature on the pharmacoeconomics of traditional Chinese medicines in China from 2018 to 2022[J].ZHONGGUO YAOFANG,2023,34(19):2378-2384. DOI： 10.6039/j.issn.1001-0408.2023.19.13.

摘要

目的

评估2018－2022年我国中药药物经济学研究文献的质量，了解国内中药药物经济学研究的发展状况和问题，为今后中药药物经济学的规范化研究提供参考。

方法

系统检索国内外有关数据库，获取2018年1月1日－2022年11月21日我国公开发表的中药药物经济学研究文献，对文献的基本情况、研究概况、药物经济学评价方法与内容进行总结；使用CHEERS 2022清单对文献质量进行评价，通过统计每篇文献具体条目的得分计算文献总得分，并将文献质量划分为优秀、良好、合格和不合格。

结果

共纳入71篇研究，包括60篇中文文献和11篇英文文献。53.52%的文献有基金支持；研究最多的中药剂型为注射剂（31.03%）；仅有不到半数（46.48%）的文献报告了研究角度；以短期经济性评价为主（69.01%）；中文研究以成本-效果分析为主（70.00%），英文研究以成本-效用分析为主（54.55%）。文献质量评价的平均得分为11.02分，其中2篇文献（2.82%）质量为良好，9篇文献（12.68%）质量为合格，大多数文献（84.51%）质量不合格。中文文献平均得分9.98分，英文文献平均得分16.73分，后者质量明显优于前者。

结论

目前中药药物经济学研究主要存在对照组干预措施的选择缺乏科学性、成本测算不规范、研究时限选取不合理、健康产出指标的证据质量有待提高、评价方法的选择有待完善、阈值的选择缺乏科学依据等问题。为支持高水平中药药物经济学研究的实施与开展，政策制定者需创造良好的政策环境并制定符合中医药特点的药物经济学评价指南，以促进评价结果的应用转化。

Abstract

OBJECTIVE

To evaluate the quality of research literature on pharmacoeconomics of traditional Chinese medicine （TCM） in China from 2018 to 2022， to understand the development status and problems of TCM pharmacoeconomic research in China， and to provide a reference for future standardized research on this field.

METHODS

The systematic search of relevant databases at home and abroad was conducted to obtain the published literature on TCM pharmacoeconomic research in China from January 1， 2018 to November 21， 2022 to summarize the basic information of the literature， the research profile， the method and content of pharmacoeconomic evaluation and to evaluate the quality of the literature by using the CHEERS 2022 checklist； calculate the total literature score by counting the scores of the specific entries of each piece of literature and classifying the quality of the literature as excellent， good， qualified， and unqualified.

RESULTS

A total of 71 studies were included， involving 60 in Chinese and 11 in English， and 53.52% of the literature was supported by grants； the most studied TCM dosage form was injection （31.03%）； less than half （46.48%） of the literature reported the study angle； short-term economic evaluation was predominantly used （69.01%）； the Chinese studies were dominated by cost-effectiveness analyses （70.00%）， and the English studies were dominated by cost-utility analysis （54.55%）. The average score of literature quality evaluation was 11.02， with two （2.82%） of the literature being of good quality， nine （12.68%） of the literature being of qualified quality， and the majority of the literature （84.51%） being of unqualified quality. The average score of Chinese literature was 9.98， and the average score of English literature was 16.73， with the quality of the latter being significantly better than that of the former.

CONCLUSIONS

At present， the pharmacoeconomic researches of TCM mainly has problems such as lack of scientific selection of intervention in the control group， nonstandard cost measurement， unreasonable selection of research time limit， quality of evidence for health output indicators to be improved， selection of evaluation methods to be improved， and lack of scientific basis for threshold selection. In order to support the implementation and development of high-level pharmacoeconomics research on TCM， policymakers need to create a favorable policy environment and formulate pharmacoeconomic evaluation guidelines that meet the characteristics of TCM， so as to promote the application and transformation of evaluation results.

关键词

中药药物经济学文献研究质量评价

Keywords

pharmacoeconomicsliterature researchquality evaluation

references

杜丽侠，王常颖，何江江，等. 药物经济学领域系统综述发展现状研究[J]. 中国卫生资源，2015，18（3）：226-228.

DU L X，WANG C Y，HE J J，et al. The development status of systematic reviews in pharmacoeconomics field[J].Chin Health Resour，2015，18（3）：226-228.

YANG N，ZHANG H H，DENG T Y，et al. Systematic review and quality evaluation of pharmacoeconomic studies on traditional Chinese medicines[J]. Front Public Health，2021，9：706366.

夏凌三，王荣，杨兆梅. 四种脑梗死治疗方案的药物经济学再分析[J]. 药物流行病学杂志，1997，6（3）：167-169，196.

XIA L S，WANG R，YANG Z M. The pharmaco-economical analysis of treatment of cerebral infarction[J]. Chin J Pharmacoepidemiol，1997，6（3）：167-169，196.

杨男，范红媛，田燕，等. 我国中药药物经济学研究系统评价和质量评估[J]. 中国研究型医院，2017，4（6）：50-58.

YANG N，FAN H Y，TIAN Y，et al. Systematic analysis and quality evaluation for pharmacoeconomics researches on traditional Chinese medicine[J]. J Chin Res Hosp，2017，4（6）：50-58.

孙晓，郭利平，商洪才，等. 国内中药药物经济学评价的系统评价及质量评估[J]. 中国中药杂志，2015，40（10）：2050-2053.

SUN X，GUO L P，SHANG H C，et al. Systematic economic assessment and quality evaluation for traditional Chinese medicines[J]. China J Chin Mater Med，2015，40（10）：2050-2053.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：4.

LIU G E. China guidelines for pharmacoeconomic evaluations 2020[M]. Beijing：China Market Press，2020：4.

罗琼，周黎，冯海欢，等. 基于中国人群的糖尿病治疗药物经济学评价文献的系统评估和质量评价[J]. 中国药房，2022，33（10）：1225-1232.

LUO Q，ZHOU L，FENG H H，et al. Systematic assessment and quality evaluation of literatures on economic evaluation of diabetes drugs in Chinese population[J].China Pharm，2022，33（10）：1225-1232.

徐蕴，王庆，黄芳，等. 基于中国期刊全文数据库的我国药物经济学评价研究文献的计量学分析[J]. 中国药房，2019，30（15）：2101-2104.

XU Y，WANG Q，HUANG F，et al. Bibliometric analysis of pharmacoeconomic evaluation research literatures in China based on Chinese journal full-text database[J]. China Pharm，2019，30（15）：2101-2104.

林洁，王硕，郭冬梅. 2014－2018年我国中药药物经济学研究文献质量评价[J]. 临床药物治疗杂志，2019，17（11）：49-52.

LIN J，WANG S，GUO D M. Literature of Chinese herbal medicine economics research from 2014 to 2018：a quality assessment[J]. Clin Med J，2019，17（11）：49-52.

冯莎，祁方家，卢建龙，等. 对国内近5年药物经济学评价文献的系统分析与评估[J]. 上海医药，2015，36（1）：14-17.

FENG S，QI F J，LU J L，et al. Systems analysis and evaluation of Chinese pharmacoeconomic literatures over five years[J]. Shanghai Med Pharm J，2015，36（1）：14-17.

HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F，et al. Consolidated health economic evaluation reporting standards 2022 （CHEERS 2022） statement：updated reporting guidance for health economic evaluations[J]. Value Health，2022，25（1）：3-9.

SULTANA M，SARKER A R，ALI N，et al. Economic evaluation of community acquired pneumonia management strategies：a systematic review of literature[J]. PLoS One，2019，14（10）：e0224170.

HOPE S F，WEBSTER J，TRIEU K，et al. A systematic review of economic evaluations of population-based sodium reduction interventions[J]. PLoS One，2017，12（3）：e0173600.

PALFREYMAN S J，STONE P W. A systematic review of economic evaluations assessing interventions aimed at preventing or treating pressure ulcers[J]. Int J Nurs Stud，2015，52（3）：769-788.

夏如玉，梁婉娴，刘春晖，等. 7种口服中成药联合三联疗法治疗幽门螺杆菌相关性消化性溃疡和胃炎的经济学评价[J]. 中国药物经济学，2022，17（4）：29-38.

XIA R Y，LIANG W X，LIU C H，et al. Economic evalua- tion of seven oral Chinese patent medicines combined with triple therapy for Helicobacter pylori related peptic ulcer and gastritis[J]. China J Pharm Econ，2022，17（4）：29-38.

王卓珏，李元霞，庞随军. 阿奇霉素联合口服中成药治疗儿童支原体肺炎的Meta分析及药物经济学评价[J]. 中国药物经济学，2022，17（7）：25-30，38.

WANG Z J， LI Y X， PANG S J. Meta analysis and pharmacoeconomic evaluation of azithromycin combined with oral Chinese patent medicine in the treatment of Mycoplasma pneumonia in children[J]. China J Pharm Econ，2022，17（7）：25-30，38.

刘峘，崔鑫，谢雁鸣，等. 香菊胶囊治疗慢性鼻-鼻窦炎的药物经济学评价[J]. 中国中药杂志，2022，47（14）：3950-3955.

LIU H， CUI X， XIE Y M， et al. Pharmacoeconomic evaluation of Xiangju capsules in treatment of chronic rhinosinusitis[J]. China J Chin Mater Med，2022，47（14）：3950-3955.

周黎，项予良，郭昭婷，等. 银杏内酯注射液对比丁苯酞注射液治疗大动脉粥样硬化性缺血性脑卒中的最小成本分析[J]. 中国药房，2020，31（18）：2235-2239.

ZHOU L，XIANG Y L，GUO Z T，et al. Cost-minimization analysis of Ginkgolide injection versus Butylphthalide injection in the treatment of ischaemic stroke of large-artery atherosclerosis[J]. China Pharm，2020，31（18）：2235-2239.

唐显帅，郑磊，张明珠，等. 基于循证医学证据和药物经济学模型的中成药临床综合评价[J]. 中国药房，2022，33（15）：1870-1875.

TANG X S，ZHENG L，ZHANG M Z，et al. Clinical comprehensive evaluation for Chinese patent medicine based on evidence-based medicine and pharmacoeconomic model[J]. China Pharm，2022，33（15）：1870-1875.

XIANG Y L，YANG N，GUO Z T，et al. Cost-effectiveness analysis of Ginkgolide injection in the treatment of ischemic stroke based on a randomized clinical trial[J]. J Altern Complement Med，2021，27（4）：331-341.

HU M，DING P，MA J F，et al. Cost-effectiveness analysis of the TCM “Yupingfeng granules” in the treatment of acute exacerbations of COPD based on a randomized clinical trial[J]. Int J Chron Obstruct Pulmon Dis，2022，17：2369-2379.

SHI H H，GUO W J，ZHU H，et al. Cost-effectiveness analysis of Xiyanping injection （andrographolide sulfonate） for treatment of adult community acquired pneumonia：a retrospective，propensity score-matched cohort study[J]. Evid Based Complement Alternat Med，2019，2019：4510591.

ZHOU J，LIU F，JIANG W L，et al. Cost-effectiveness of Jingshu granules compared to placebo for the treatment of patients with cervical radiculopathy in China：a decision-tree model based on randomized controlled trial[J]. J Altern Complement Med，2019，25（12）：1183-1192.

LIU G，HUANG Z Y，XIN Q. Cost-effectiveness of oral antidiabetic drugs：a prospective multicenter study of real-world patients[J]. Evid Based Complement Alternat Med，2021，2021：9972386.

XUAN J W，HUANG M，LU Y J，et al. Economic evaluation of Safflower yellow injection for the treatment of patients with stable angina pectoris in China：a cost-effectiveness analysis[J]. J Altern Complement Med，2018，24（6）：564-569.

YU X Q，YANG S G，LI H，et al. Preliminary study to evaluate three different treatments on stable chronic obstructive pulmonary disease patients based on Markov model[J]. Evid Based Complement Alternat Med，2019，2019：6478926.

LU L，LI Y，JIN Q C，et al. Safflor yellow treating angina pectoris：a pharmacoeconomic evaluation and network meta-analysis[J]. Medicine，2022，101（41）：e31036.

LI Y，LIN Y，SHI Z X，et al. Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction：a systematic review，meta-analysis，and cost-effectiveness analysis[J]. Ann Transl Med，2021，9（18）：1407.

XU Q，YANG N，FENG S，et al. Cost-effectiveness analysis of combining traditional Chinese medicine in the treatment of hypertension：compound Apocynum tablets combined with Nifedipine sustained-release tablets vs Nifedi- pine sustained-release tablets alone[J]. BMC Complement Med Ther，2020，20（1）：330.

SONG Z，SUN L Y，GU S S，et al. Exploring the safety，effectiveness，and cost-effectiveness of a Chinese patent medicine （Fufang e’jiao syrup） for alleviating cancer-related fatigue：a protocol for a randomized，double-blinded，placebo-controlled，multicenter trial[J]. Integr Cancer Ther，2021，20：15347354211002919.

DRUMMOND M F，SCULPHER M J，CLAXTON K， et al. Methods for the economic evaluation of healthcare programs[M]. Fourth edition. Oxford：Oxford University Press，2015：1-396.

陈昌明，刘杰，张英，等.晚期非小细胞肺癌患者三种治疗方案经济学评价[J].中国中医基础医学杂志，2018，24（4）：507-509，529.

CHEN C M，LIU J，ZHANG Y，et al. Economic evaluation of three treatment regimens for advanced non-small cell lung cancer[J]. Chin J Basic Med Tradit Chin Med，2018，24（4）：507-509，529.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Preparation and quality evaluation of Eriodictyol chewable tablet

Quality analysis of Codonopsis pilosula with different commodity specification grades

Quality evaluation of Indigo Naturalis based on multi-component quantification combined with chemometrics

Comprehensive quality evaluation of Periploca forrestii produced in Guizhou using multi-index components combined with multivariate statistical analysis

Quality evaluation of total flavonoids of Lamiophlomis rotata from different producing areas

Related Author

QIN Chunmeng

LI Wenjun

LI Liaoping

LIU Jie

LIU Songqing

ZHANG Xiaohui

TONG Liguo

WANG Yibing

Related Institution

Chongqing Liyang Medical Pharmaceutical Development Co.， Ltd.

Dept. of Pharmacy， the Third Affiliated Hospital of Chongqing Medical University

College of Pharmacy， Chongqing Medical University

Dept. of Pharmacy， Shanxi Hospital of Traditional Chinese Medicine

Dept. of Pharmacy， Changzhi Medical College

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰